A Dietary Supplement in Treatment of Glaucoma
About the Research Project
Program
Award Type
Standard
Award Amount
$180,000
Active Dates
September 01, 2020 - August 31, 2024
Grant ID
G2020286
Co-Principal Investigator(s)
Ying Li, MD, PhD, Emory University
Goals
Mitochondria are the energy factories of cells. The mitochondria of RGCs lose function with age, probably due to age-related loss of nicotinamide adenine dinucleotide (NAD+), an enzyme cofactor needed for energy production, making the cells more susceptible to damage. The goal of this study is to test whether systemic delivery of the NAD+ precursor nicotinamide riboside, a dietary supplement, increases retinal NAD+ and protects RGCs in glaucoma models.
Summary
The mitochondria of retinal ganglion cells lose function with age, probably due to age-related loss of nicotinamide adenine dinucleotide (NAD+), an enzyme cofactor needed for energy production. The cells thus become more susceptible to damage from, for instance, elevated pressure in the eye, a common risk factor for glaucoma. We propose to test whether systemic delivery of the NAD+ precursor nicotinamide riboside, a dietary supplement, increases retinal NAD+ and protects retinal ganglion cells in mouse models of glaucoma.
Related Grants
National Glaucoma Research
Understanding Optic Nerve Head Astrocyte Contributions to Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Evan Cameron, PhD
Current Organization
Cleveland Clinic - Lerner Research Institute
Understanding Optic Nerve Head Astrocyte Contributions to Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Evan Cameron, PhD
Current Organization
Cleveland Clinic - Lerner Research Institute
National Glaucoma Research
Exploring Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Qi Cui, MD, PhD
Current Organization
University of Pennsylvania, Perelman School of Medicine
Exploring Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Qi Cui, MD, PhD
Current Organization
University of Pennsylvania, Perelman School of Medicine
National Glaucoma Research
Reducing Inflammation to Protect Vision in Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Cátia Gomes, PhD
Current Organization
Indiana University School of Medicine
Reducing Inflammation to Protect Vision in Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Cátia Gomes, PhD
Current Organization
Indiana University School of Medicine